The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency. According to an update from the Food and Drug ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback